SynAct Pharma Informs about Termination of Coverage Agreement with Redeye

SynAct Pharma AB (“SynAct Pharma”) hereby informs that the company has terminated the agreement with Redeye relating to the coverage of the company.

For further information, please contact:

Jeppe Øvlesen                                                                               

CEO, SynAct Pharma AB                                                               

Phone: +45 28 44 75 67                                                                 
Mail: [email protected]